Evaluation of Moclobemide, a Reversible MAO-A Inhibitor, as an Adjunct to Nicotine Replacement Therapy in Female Smokers
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
The proposed study will assess the efficacy of moclobemide, a selective, reversible MAO-A
inhibitor, in facilitating smoking cessation in treatment-seeking female smokers. This
rationale is based on several findings from previous work: 1) cigarette smoke contains
constituents that inhibit both forms of the enzyme monoamine oxidase (MAO-A and MAO-B); 2)
that severity of depression symptoms after smoking abstinence is correlated with the level of
MAO-A inhibition previously obtained from smoking; 3) moclobemide, an MAO-A inhibitor was
found efficacious in a smoking cessation treatment trial (Berlin et al., 1995); and 4) women
show a greater association between smoking and depression than men and women smokers in our
previous trials report smoking to alleviate symptoms of depression to a greater extent than
men.
Phase:
Phase 2
Details
Lead Sponsor:
Jed E. Rose
Collaborators:
National Institute on Drug Abuse (NIDA) Philip Morris USA, Inc.